Cilostazol Dexborneol Versus Placebo for Microcirculation Dysfunction After Reperfusion Therapy in Patients With Acute Ischemic Stroke With Large Vessel Occlusion
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.
Also called NCT05836766
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 120 participants
- Registry
-
NCT05836766
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT05836766. Randomized; quadruple masking; primary purpose treatment. Start 2023-06-05 (actual); primary completion 2024-07 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Cilostazol Dexborneol Versus Placebo for Microcirculation Dysfunction After Reperfusion Therapy in Patients With Acute Ischemic Stroke With Large Vessel Occlusion
- Acronym
- CRYSTAL
- Condition
- Acute Ischemic Stroke
- Condition
- Reperfusion
- Condition
- Large Vessel Occlusion
- Intervention (Drug)
- Y-6 sublingual tablets
- Intervention (Drug)
- Placebo tablets of Y-6 sublingual tablet
- Lead sponsor
- Beijing Tiantan Hospital
- Collaborator
- Neurodawn Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct05836766- Content hash
734e859f815e677c428c41a7013a8a52ee9ff1d5de2aa3c34bf383a5794e0fcf